The SII request for approval of the emergency use of the Covid vaccine will be considered today.
New Delhi:
The Serum Institute of India’s application for emergency use approval for the coronavirus vaccine developed by the University of Oxford and major drugmaker AstraZeneca will be considered by a panel of experts today, sources told NDTV, hours after the United Kingdom gave the same authorization.
The director of the Serum Institute, Adar Poonawalla, expressed his happiness for the decision. “This is excellent and encouraging news. We will await final approval from Indian regulators,” he told NDTV.
Last month, the Serum Institute, which makes the AstraZeneca vaccine, said that a positive result from a late state test would allow it to seek approval before the end of the year for its candidate’s emergency use, before obtaining approval for introduction. complete in February or March.
India also expects a government-backed vaccine to be released starting in February. It is also conducting a test on the last stage of Sputnik V.
The UK on Wednesday approved the University of Oxford-AstraZeneca vaccine for human use, the second coronavirus vaccine to be licensed for deployment in Britain after the Pfize-BioNTech attacks.
The Oxford vaccine was being evaluated by the British regulator, the Medicines and Health Products Regulatory Agency (MHRA), after the government released the final data cut last week.
MHRA approval means the vaccine is “safe and effective” and the UK government’s Department of Health and Social Care (DHSC) said the National Health Service (NHS) will prioritize administering the first of the two. doses of the vaccine to those in the highest risk groups rapidly.
“It is really fantastic news, and a triumph for British science, that the vaccine has been approved for use. We are now going to act to vaccinate as many people as possible as quickly as possible,” said British Prime Minister Boris Johnson. .
The UK Joint Committee on Vaccination and Immunization (JCVI) will issue updated advice for priority groups to receive the new vaccine, which is similar in that it requires two doses but is easier to administer as it does not require extremely low temperatures. for storage as in the case of Pfizer-BioNTech strokes.
It is also cheap and easy to mass produce and is intended to significantly improve the UK vaccination program against the deadly virus.
.
